CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
TAK-906 Oral Capsule +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04454918
NCT04454918Phase 1Completed
CompareCT.gov

A Phase 1 Study to Assess Absolute Bioavailability of TAK-906 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Subjects

Millennium Pharmaceuticals, Inc.·interventional·Posted Jul 2, 2020·Updated Mar 7, 2022

In Brief

A Phase 1 clinical trial evaluating TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, and 1 other intervention for Healthy Volunteers. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to determine ABA of TAK-906 following single oral (capsule) administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose administration of 100 microgram (μg) (approximately 1 microcurie \[μCi\]) of \[14C\]-TAK-906 in Period 1 (ABA), and to determine the mass balance of TAK-906 in urine and feces following a single oral (solution) administration of 50 mg (approximately 100 μCi) of \[14C\]-TAK-906 in Period 2 (absorption, distribution, metabolism, and elimination \[ADME\]).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedJul 2, 2020
Enrollment StartJul 30, 2020
Primary CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6 years ago

Interventions

TAK-906 Oral Capsuledrug

TAK-906 capsule.

[14C]-TAK-906 Intravenous Infusiondrug

\[14C\]-TAK-906 intravenous infusion.

[14C]-TAK-906 Oral Solutiondrug

\[14C\]-TAK-906 oral solution.